Vitamin D3 and deconvoluting a rash.

Area of Science:

• Immunology
• Dermatology
• Pharmacology

Background:

• Adverse drug reactions pose clinical challenges due to unpredictable immunologic responses.
• Systemic cholecalciferol (vitamin D3) possesses known immunomodulatory properties.
• Investigating vitamin D3's effects on experimentally induced skin inflammation is crucial.

Purpose of the Study:

• To evaluate the clinical and molecular immunomodulatory effects of a single high dose of oral vitamin D3.
• To assess vitamin D3's impact on an experimentally induced chemical rash in healthy adults.
• To explore vitamin D3's potential as a treatment for severe inflammatory reactions.

Main Methods:

• A randomized, double-blinded, placebo-controlled trial involving 28 healthy adults.
• Skin inflammation induced by topical nitrogen mustard (NM), followed by repeat exposure and either placebo or 200,000 IU cholecalciferol.
• Clinical, serum, skin tissue, and multi-omic analyses conducted over 6 weeks.

Main Results:

• Cholecalciferol significantly mitigated acute inflammation and demonstrated durable responses for 6 weeks.
• An unexpected divergence in NM response severity was observed, linked to systemic neutrophilia and distinct histopathology.
• A unique 3-biomarker signature (CCL20, CCL2, CXCL8) in exaggerated responders, implicating IL-17 signaling, was suppressed by cholecalciferol.

Conclusions:

• High-dose systemic cholecalciferol is a potential effective treatment for severe reactions to topical chemotherapy.
• Vitamin D3 demonstrates broad anti-inflammatory potential against exaggerated immune responses.
• Findings support further investigation of vitamin D3 in managing inflammatory conditions.